
Feature|Videos|July 21, 2025
How New Policies are Impacting Market Sustainability
Industry stakeholders suggest how pharmaceutical companies can proactively plan for the potential implementation of a Most Favored Nation (MFN) pricing model.
Advertisement
Episodes in this series

The Most Favored Nation (MFN) pricing policy aims to align US drug prices with lower international rates. The panelists share varying perspectives on this policy, including its uncertain future, the need for greater pricing transparency, and how manufacturers might defend price differences based on value, clinical investment, and regulatory requirements. Also discussed are potential overlaps with the Inflation Reduction Act and the crucial role that proactive advocacy plays in a changing policy landscape.
Key discussion topics include:
- The potential impact of MFN pricing on US drug costs and the current market.
- Why pricing transparency and value justification are increasingly essential for pharmaceutical companies.
- The role of scenario planning and value proposition refinement in navigating regulatory uncertainty.
Advertisement
Related to this article

Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.

Innogen grants Arcera exclusive rights to its long-acting GLP-1 receptor agonist across Africa, Eastern Europe, Latin America and the Middle East.

With rising healthcare costs, practices are embracing flexible payment models and upfront pricing transparency to keep care accessible.

Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.

Novartis narrowed its mid-term sales growth outlook to 5% annually through 2031 at its London investor day, as patent expirations weigh on the Swiss drugmaker.

DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Advertisement
Advertisement
Trending on PharmExec
1
Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks
2
Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera
3
FDA Approves Livsayis, Regeneron's First siRNA Therapy for Myasthenia Gravis
4
DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
5


